Biogen (BIIB) Revenue by Segment

History

Date	Multiple Sclerosis	Other	Rare Disease	Biosimilars
Jun 30, 2025	4.18B	2.85B	2.14B	761.10M
Mar 31, 2025	4.23B	2.64B	2.13B	777.50M
Dec 31, 2024	4.35B	2.49B	1.99B	793.60M
Sep 30, 2024	4.45B	2.39B	1.87B	779.80M
Jun 30, 2024	4.55B	2.42B	1.82B	777.50M
Mar 31, 2024	4.61B	2.47B	1.72B	774.50M
Dec 31, 2023	4.66B	2.59B	1.74B	770.00M
Sep 30, 2023	4.76B	2.67B	1.79B	756.60M
Jun 30, 2023	4.94B	2.50B	1.77B	749.90M
Mar 31, 2023	5.16B	2.42B	1.76B	749.20M
Dec 31, 2022	5.43B	2.19B	1.79B	751.10M
Sep 30, 2022	5.69B	2.09B	1.78B	797.20M
Jun 30, 2022	5.91B	2.11B	1.79B	812.40M
Mar 31, 2022	6.01B	2.12B	1.86B	820.40M
Dec 31, 2021	6.10B	2.13B	1.91B	831.20M
Sep 30, 2021	6.17B	2.15B	1.96B	807.80M
Jun 30, 2021	6.60B	2.26B	2.01B	812.90M
Mar 31, 2021	7.20B	2.61B	2.01B	782.10M
Dec 31, 2020	7.83B	2.75B	2.05B	795.80M
Sep 30, 2020	8.41B	2.95B	2.10B	794.20M

Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.